Mr. Moran is an experienced senior executive, having served for 25 years as the Chief Executive Officer (CEO) for a number of prominent national health foundations and consulting organizations focused on expanding medical knowledge and guiding new therapies from development through clinical trials to licensure and successful commercialization. Access Therapeutics’ clients are international manufacturers, US specialty distributors and specialty pharmacies, and national patient advocacy organizations.
A partial listing of recent engagements includes Amerisource Bergen Specialty Group (ASD Healthcare and US Bioservices), Centric Health Resources, FFF Enterprises, Talecris Biotherapeutics, ZLB Behring and two Israeli biologics enterprises. Mr. Moran has collaborative relationships with the US FDA involving initiatives designed to address critical product shortages, to streamline licensure requirements for therapies intended for rare disease populations, and to manage clinical trials for non-US manufacturers seeking to meet these needs. He has testified and provided key data to FDA, HHS, and CDC advisory committees and senior staff. Mr. Moran has worked closely with the US Congress and with key legislators and staff on relevant public health issues resulting in legislative directives and support.
On behalf of the organizations he has led, Mr. Moran has worked with Congress and the NIH to establish multi-year and multi-center medical research programs and consortia. Mr. Moran’s therapeutic experience includes plasma derivatives (e.g. IGIV, clotting factors, and hyperimmunes), transgenic and biotech proteins, and novel gene therapy approaches.
Mr. Moran holds a BA in Economics from Boston College. He currently serves on the National Corporate Advisory Council for The Neuropathy Association and is an Officer and Treasurer for the Board of Directors of the Beth Tfiloh Community Day School serving 1,000 students in Baltimore, Maryland.